"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Descriptor ID |
D004357
|
MeSH Number(s) |
G07.690.773.968.477
|
Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 10 | 10 |
1995 | 0 | 8 | 8 |
1996 | 0 | 8 | 8 |
1997 | 0 | 11 | 11 |
1998 | 0 | 10 | 10 |
1999 | 0 | 11 | 11 |
2000 | 0 | 12 | 12 |
2001 | 0 | 13 | 13 |
2002 | 0 | 22 | 22 |
2003 | 0 | 14 | 14 |
2004 | 1 | 25 | 26 |
2005 | 0 | 23 | 23 |
2006 | 1 | 37 | 38 |
2007 | 0 | 23 | 23 |
2008 | 1 | 30 | 31 |
2009 | 0 | 30 | 30 |
2010 | 1 | 40 | 41 |
2011 | 0 | 32 | 32 |
2012 | 0 | 27 | 27 |
2013 | 2 | 24 | 26 |
2014 | 1 | 24 | 25 |
2015 | 0 | 24 | 24 |
2016 | 0 | 25 | 25 |
2017 | 0 | 26 | 26 |
2018 | 2 | 20 | 22 |
2019 | 1 | 23 | 24 |
2020 | 1 | 17 | 18 |
2021 | 0 | 11 | 11 |
2022 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep. 2022 07 29; 12(1):12984.
-
Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. Pharm Res. 2022 Mar; 39(3):511-528.
-
Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma. 2022 07; 63(7):1634-1644.
-
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921.
-
Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood. 2021 10 28; 138(17):1637-1641.
-
Assessing Performance of Bronchoscopic Diagnostic Techniques: Looking for Combinations That Offer Synergy. Chest. 2021 10; 160(4):1181-1183.
-
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022 01; 35(1):66-77.
-
Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling. Mol Cancer Ther. 2021 08; 20(8):1469-1480.
-
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat Commun. 2021 05 10; 12(1):2606.
-
Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Mol Cancer Ther. 2021 07; 20(7):1257-1269.